As more of your hospital and surgeon customers embrace value-based healthcare, it is imperative to understand how you play a role in this reimbursement shift.
Advancements in orthobiologics have effects across all market segments. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the orthobiologics market—as it stands now, and where it’s heading tomorrow.
At OMTEC
® 2019, surgeons were clear: they are interested in leveraging innovations in materials, robotics, AI and wearables for the benefit of their patients and their practices. They will look to the data to measure progress.
NuVasive capitalized on the advantages of AM, going from design to market in just over one year with the 2017 launch of Modulus—now a full implant line.
This month's articles on value analysis, biologic development and device distribution brought to mind last year's discussion with Patrick Sweeney, M.D. Revisit the diverse interests of this surgeon inventor.
